ArticleJournal of molecular medicine (Berlin, Germany)2026
SREBF2 promotes mitophagy and protects against ferroptosis via Cav-1-regulated PINK1/Parkin signaling in ischemic heart failure.
Article in Journal of molecular medicine (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Myocardial infarction-induced heart failure (MI-HF) remains a major contributor to cardiovascular mortality, yet the molecular mechanisms underlying its progression, particularly those involving ferroptosis, are not fully understood. This study aimed to investigate the role of SREBF2 in regulating ferroptosis and mitochondrial homeostasis in MI-HF. Differentially expressed genes were screened from the GSE24519 dataset and overlapped with ferroptosis-related genes, identifying SREBF2 as a potential target. SREBF2 expression was examined in human HF samples, MI-HF mice, and oxygen-glucose deprivation (OGD)-injured cardiomyocytes. Functional roles of SREBF2 were evaluated through in vivo overexpression in mice and in vitro assays in cardiomyocytes. Ferroptosis markers (GPX4, ACSL4, ROS, MDA, Fe²⁺, GSH), mitochondrial membrane potential (ΔΨm), and mitophagy-related proteins (PINK1, Parkin, p62) were assessed. Chromatin immunoprecipitation and rescue experiments were conducted to confirm the transcriptional regulation of Caveolin-1 (Cav-1) by SREBF2. SREBF2 was significantly downregulated in MI-HF tissues and OGD-injured cardiomyocytes. Overexpression of SREBF2 improved cardiac function, reduced infarct size and fibrosis, and enhanced myocardial remodeling in MI-HF mice. SREBF2 suppressed ferroptosis by reducing ROS, Fe²⁺, and MDA levels, restoring GSH and GPX4, and downregulating ACSL4. Mitochondrial dysfunction was alleviated via improved ΔΨm, reduced mitoROS, and balanced mitochondrial dynamics. SREBF2 activated PINK1/Parkin-mediated mitophagy, which was essential for its anti-ferroptotic effects. Mechanistically, SREBF2 directly bound to and transcriptionally activated Cav-1, which mediated downstream mitophagy activation and ferroptosis inhibition. Cav-1 knockdown or mitophagy inhibition abrogated SREBF2-induced mitochondrial protection and cytoprotection. The results of our study demonstrate that SREBF2 mitigates MI-induced HF by activating the Cav-1/PINK1/Parkin axis to promote mitophagy and inhibit ferroptosis. These findings reveal a novel cardioprotective mechanism and identify SREBF2 as a promising therapeutic target in heart failure.
Indexed as
Identifiers
42658277What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.